个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Zhang, L.[1] * ; Yang, Y.[1] ; Chen, X.[2] ; Li, J.[3] ; Pan, J.[4] ; He, X.[5] ; Lin, L.[6] ; Shi, Y.[7,8] ; Feng, W.[9] ; Xiong, J.[10] ; Yang, K.[11] ; Yu, Q.[12] ; Hu, D.[13] ; Sun, Y.[14] ; Zhang, Q.[15] ; Hu, G.[16] ; Li, P.[17] ; Shen, L.[18] ; Yang, Q.[19] ; Zhang, B.[19] ;
单位： [1]Sun Yat Sen Univ, Canc Ctr, Oncol, Guangzhou, Guangdong, Peoples R China [2]Zhejiang Canc Hosp, Head & Neck Radiotherapy, Hangzhou, Zhejiang, Peoples R China [3]Jiangxi Canc Hosp, Head Neck Radiotherapy Dept, Nanchang, Jiangxi, Peoples R China [4]Fujian Prov Canc Hosp, Dept Head & Neck Radiat Oncol, Fuzhou, Fujian, Peoples R China [5]Canc Hosp Chinese Acad Med Sci, Med Oncol, Beijing, Peoples R China [6]Guangzhou Univ Chinese Med, Affiliated Hosp 1, Tumor Ctr, Guangzhou, Guangdong, Peoples R China [7]Cent South Univ, Hunan Canc Hosp, Head & Neck Radiotherapy Dept 2, Changsha, Hunan, Peoples R China [8]Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China [9]Foshan First Peoples Hosp, Dept Head Neck & Chest Canc, Foshan, Peoples R China [10]Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang, Jiangxi, Peoples R China [11]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Canc Ctr, Wuhan, Hubei, Peoples R China [12]Guangxi Med Univ, Tumor Hosp, Resp Oncol, Nanning, Peoples R China [13]Hubei Canc Hosp, Radiat Therapy Ctr, Wuhan, Hubei, Peoples R China [14]Beijing Canc Hosp, Dept Radiat Oncol, Beijing, Peoples R China [15]Fudan Univ, Shanghai Canc Ctr, Med Oncol, Shanghai, Peoples R China [16]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Canc, Wuhan, Hubei, Peoples R China [17]Sichuan Univ, West China Hosp, Ward 1 Oncol, Chengdu, Sichuan, Peoples R China [18]Cent South Univ, Xiangya Hosp, Oncol, Changsha, Hunan, Peoples R China [19]Jiangsu Hengrui Med Co Ltd, Clin Res & Dev, Shanghai, Peoples R China
出处：
DOI： 10.1016/j.annonc.2020.08.1027
ISSN：
基金：
Jiangsu Hengrui Medicine Co., Ltd.
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2019]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2018]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者：
第一作者单位： [1]Sun Yat Sen Univ, Canc Ctr, Oncol, Guangzhou, Guangdong, Peoples R China
推荐引用方式(GB/T 7714)：
Zhang L.,Yang Y.,Chen X.,et al.A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study[J].ANNALS OF ONCOLOGY.2020,31:S659-S659.doi:10.1016/j.annonc.2020.08.1027.
APA：
Zhang, L.,Yang, Y.,Chen, X.,Li, J.,Pan, J....&Zhang, B..(2020).A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study.ANNALS OF ONCOLOGY,31,
MLA：
Zhang, L.,et al."A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study".ANNALS OF ONCOLOGY 31.(2020):S659-S659

资源点击量：426 今日访问量：0 总访问量：408 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）